Statins for Venous Event Reduction in Patients With Venous Thromboembolism

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2700 participants.

Also called NCT04319627

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 2,700 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04319627
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Canada, France, Ireland, Italy, Norway, United Kingdom (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT04319627. Randomized; quadruple masking; primary purpose treatment. Start 2021-02-10 (actual); primary completion 2028-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Statins for Venous Event Reduction in Patients With Venous Thromboembolism
Acronym
SAVER
Condition
Venous Thromboembolism
Condition
Blood Clot
Condition
Post Thrombotic Syndrome
Intervention (Drug)
Rosuvastatin Calcium
Intervention (Drug)
Placebo Oral Tablet
Lead sponsor
Ottawa Hospital Research Institute (class: other)
Collaborator
Canadian Institutes of Health Research (CIHR) (class: other government)
Collaborator
Eastern Norway Health Authorities RHF (class: not stated)
Collaborator
Southern health region, Norway (class: not stated)
Collaborator
Programme hospitalier de recherche clinique, France (class: not stated)
Collaborator
British Heart Foundation (class: other)

Record details

Record id
cardio:ct-nct04319627
Content hash
7373972b18130d70815aa8dc699734f7756c8cb3d1503e78e2c58cc82f37ca6e